|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Sexually Transmitted Diseases - An Underestimated Threat Lacking Interventions to Prevent Transmission
Datamonitor, Aug 2010, Pages: 142
Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious complications and association with increased transmission of human immunodeficiency virus (HIV). High disease burdens, low diagnosis and treatment rates, and a lack of marketed interventions for the prevention of most STDs highlight the clinical and commercial potential in this area.
Scope
- Review of epidemiology and current treatment practice for chlamydia, gonorrhea, HPV, HSV-2 across the US, Japan, France, Italy, Germany, Spain and UK
- Review of current clinical practice and key drugs and vaccines in development for sexually transmitted diseases
- Thorough assessment of key developments, opportunities and threats shaping the sector
- In-depth discussion of future strategies to improve the management of sexually transmitted diseases
Highlights of this title
The potential for prophylactic vaccines against STDs has been demonstrated by the success of marketed prophylactic human papillomavirus vaccines. Due to its wider serotype coverage, Merck & Co's Gardasil continues to outperform GlaxoSmithKline's Cervarix with annual global sales of $1.7 billion versus $292m, respectively.
Challenges for the development of vaccines against chlamydia, gonorrhea or HSV-2 include vaccine design, considering the complexity of pathogen biology and required immune response, as well as reimbursement and uptake. Successful marketing strategies could exploit the link between STDs and infertility as well as increased HIV transmission.
Improvements in rapid point-of-care diagnostic tests and the development of home-testing devices would increase currently low diagnosis and treatment rates for STDs and help to prevent transmission and long-term complications.
Key reasons to purchase this title
- Review the epidemiological and clinical factors driving new product decisions in STDs as well as unmet needs with current treatment options.
- Understand challenges, unmet needs and future opportunities by learning about the views of key opinion leaders
- Gain competitive advantage by identifying key product characteristics and potential roles for new therapies
Customers who bought this item also bought
Future Infectious Disease Nucleic Acid Testing
Emerging Microbiology Tests and Companies Developing New Technologies and Products
2012 Japan Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
2012 Italy Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
2012 France Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
Molecular Diagnostics - Technologies, Markets and Companies
Future Japanese Molecular Diagnostics Market: Growth Opportunities and Business Expansion Strategies
How to Enhance the Value of Antiviral Therapies through Biomarkers and Diagnostics
2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies
Future US Microbiology Testing Market Outlook
|
|
|
|
